We previously verified in mice xenografted with COV34-MISRII cells (OC model) that: (i) 3C23K anti-tumor efficacy was not significantly different when using different treatment schedules (2 or 3 injections of 10 mg/kg 3C23K/week for 4 or 6 weeks) (Supplementary Figure 2A) and (ii) the anti-tumor activity of 3C23K administered intraperitoneally (i.p.)or intravenously (10 mg/kg, Q3-4D12) was almost similar (Supplementary Figure 2B). Here, AMHR2 is linked to neoplasm.